سعر ميتوجليم ام 3/500مجم 30 اقراص 2022

Metoglim M film-coated tablets containing glimepiride 3 mg and metformin hydrochloride 500 mg, 30 per pack (Al Esraa Pharmaceutical Optima), a combined insulin secretagogue and sensitiser for type 2 diabetes.

• Glimepiride: most common adverse reactions are hypoglycaemia, dizziness, asthenia, headache and nausea; serious hypersensitivity reactions (anaphylaxis, angioedema, Stevens-Johnson syndrome) have been reported.General active-ingredient information · DailyMed (U.S. National Library of Medicine)

• Glimepiride: history of hypersensitivity to glimepiride or to sulfonamide derivatives.General active-ingredient information · DailyMed (U.S. National Library of Medicine)
• Metformin: severe renal impairment (eGFR below 30 mL/min/1.73 m2); hypersensitivity to metformin; acute or chronic metabolic acidosis including diabetic ketoacidosis.General active-ingredient information · DailyMed (U.S. National Library of Medicine)

• Glimepiride: all sulfonylureas can cause severe hypoglycaemia, which may impair the ability to drive and may cause unconsciousness, convulsions or death; use caution in patients predisposed to hypoglycaemia (e.g. elderly, renal impairment). Haemolytic anaemia may occur in G6PD deficiency.General active-ingredient information · DailyMed (U.S. National Library of Medicine)
• Metformin (boxed warning): post-marketing cases of metformin-associated lactic acidosis have resulted in death, hypothermia, hypotension and resistant bradyarrhythmias; risk factors include renal impairment, iodinated contrast, surgery, hypoxic states, excessive alcohol and hepatic impairment.General active-ingredient information · DailyMed (U.S. National Library of Medicine)

• Glimepiride: no drug-associated risk of major birth defects identified, but sulfonylureas cross the placenta and can cause neonatal hypoglycaemia; discontinue at least two weeks before expected delivery.General active-ingredient information · DailyMed (U.S. National Library of Medicine)
• Glimepiride: monitor breastfed infants for signs of hypoglycaemia.General active-ingredient information · DailyMed (U.S. National Library of Medicine)

• Glimepiride: Lowers blood glucose mainly by stimulating insulin release from pancreatic beta cells via binding to the sulfonylurea receptor and closure of ATP-sensitive potassium channels (US label).
• Metformin hydrochloride: Decreases hepatic glucose production, decreases intestinal absorption of glucose and improves insulin sensitivity by increasing peripheral glucose uptake and utilisation (US label). PubChem values refer to metformin base.